Jump to content

RPE65

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Petkraw (talk | contribs) at 11:56, 26 April 2021 (Clinical significance: link to article describing this gene therapy). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

RPE65
Identifiers
AliasesRPE65, BCO3, LCA2, RP20, mrd12, sretinal pigment epithelium-specific protein 65kDa, retinal pigment epithelium specific protein 65, retinoid isomerohydrolase, p63, retinoid isomerohydrolase RPE65
External IDsOMIM: 180069; MGI: 98001; HomoloGene: 20108; GeneCards: RPE65; OMA:RPE65 - orthologs
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_000329

NM_029987

RefSeq (protein)

NP_000320

NP_084263

Location (UCSC)Chr 1: 68.43 – 68.45 MbChr 3: 159.3 – 159.33 Mb
PubMed search[3][4]
Wikidata
View/Edit HumanView/Edit Mouse

Retinal pigment epithelium-specific 65 kDa protein, also known as retinoid isomerohydrolase, is an enzyme of the vertebrate visual cycle that is encoded in humans by the RPE65 gene.[5][6] RPE65 is expressed in the retinal pigment epithelium (RPE, a layer of epithelial cells that nourish the photoreceptor cells) and is responsible for the conversion of all-trans-retinyl esters to 11-cis-retinol during phototransduction.[7] 11-cis-retinol is then used in visual pigment regeneration in photoreceptor cells.[8][9] RPE65 belongs to the carotenoid oxygenase family of enzymes.[8]

Function

RPE65 is a critical enzyme in the vertebrate visual cycle found in the retinal pigmented epithelium. It is also found in rods and cones.[10] The photoisomerization of 11-cis-retinal to all-trans-retinal initiates the phototransduction pathway through which the brain detects light. All-trans-retinol is not photoactive and therefore must be reconverted to 11-cis-retinal before it can recombine with opsin to form an active visual pigment.[8][11] RPE65 reverses the photoisomerization by converting an all-trans-retinyl ester to 11-cis-retinol. Most commonly, the ester substrate is retinyl palmitate. The other enzymes of the visual cycle complete the reactions necessary to oxidize and esterify all-trans-retinol to a retinyl ester (RPE65's substrate) and to oxidize 11-cis-retinol to 11-cis-retinal (the required photoactive visual pigment component).[8][9]

The reaction completed by RPE65 in the retinoid cycle.

RPE65 is also referred to as retinol isomerase or retinoid isomerase, owing to past debates about the enzyme's substrate and whether it was involved in ester hydrolysis.[9]

Structure

RPE65 is a dimer of two symmetrical, enzymatically independent subunits. The active site of each subunit has a seven-bladed beta-propeller structure with four histidines that hold an iron(II) cofactor.[9][12] This structural motif is common across the studied members of the carotenoid oxygenase family of enzymes. RPE65 is strongly associated with the membrane of the smooth endoplasmic reticulum in RPE cells.[8]

Active site structure

The active site of each RPE65 active site contains an Fe(II) cofactor bound by four histidines (His180, His241, His313, and His527), each contributed by a separate blade on the beta-propeller structure. Three of the four histidines are coordinated to nearby glutamic acid residues (Glu148, Glu417, and Glu469), which are thought to help position the histidines to bind the iron cofactor in an octahedral geometry.[13] Phe103, Thr147, and Glu148 surround the active site where they help stabilize the carbocation intermediate and increase the stereoselectivity of RPE65 for 11-cis-retinol over 13-cis-retinol.[9]

The RPE65 iron(II) cofactor, showing its coordination with 4 histidine residues and 3 glutamic acid residues.

Reactants and products likely enter and leave the active site through a hydrophobic tunnel which is thought to open into the lipid membrane for direct lipid substrate absorption. A second, smaller tunnel also reaches the active site and may serve as a pathway for water, but is too narrow to transport the retinoid reactants and products.[9][13]

Membrane interactions

RPE65 is strongly associated with the membrane of the sER. sER is abnormally abundant in RPE cells due to their role in processing lipidic retinoids. Structural studies indicate that RPE65 is partially imbedded in the sER membrane via interactions between its hydrophobic face and the interior of the lipid membrane. This is supported by the need for detergent to solubilize RPE65. A major portion of RPE65's hydrophobic face, residues 109–126, forms an amphipathic alpha helix that likely contributes to the protein's membrane affinity. Additionally, Cys112 is palmitoylated in native RPE65, further supporting the theory that the hydrophobic face of RPE65 is imbedded in the membrane.[13]

The hydrophobic face contains the entrance to the large tunnel that leads to the enzyme's active site. The presence of this channel on the hydrophobic face combined with RPE65's demonstrated ability to absorb substrate direction from the lipid bilayer is consistent with RPE65 being partially embedded in the membrane.[8]

Conservation

RPE65 has been isolated from a wide range of vertebrates including zebra fish, chicken, mice, frogs, and humans.[8][14][15] Its structure is highly conserved between species, particularly in the beta-propeller and likely membrane bound regions. The amino acid sequences of human and bovine RPE65 differ by less than 1%.[13] The histidine residues of the beta-propeller structure and the bound iron(II) cofactor are 100% conserved across studied RPE65 orthologs and other members of the carotenoid oxygenase family.[9]

Soluble RPE65 (sRPE65)

Previously, it was proposed that RPE65 exists in two, interconverted forms: membrane bound mRPE65 and soluble sRPE65. This theory suggested that the reversible conversion of sRPE65 to mRPE65 by palmitoylation at Cys231, Cys329, and Cys330 played a role in regulating the retinoid cycle and endowing mRPE65 with its membrane affinity.[16] However, crystallographic studies of RPE65 have demonstrated that these residues are neither palmitoylated nor surface facing. New studies have also failed to confirm the presence of abundant soluble RPE65. Thus, this theory has been largely abandoned.[8][13]

Mechanism

The proposed RPE65 O-alkyl cleavage mechanism. The residues shown are, clockwise from top left - Phe103, Thr147, His313, His527, His180, His241, and Glu148.

RPE65 catalyzes the conversion of all-trans-retinyl ester to 11-cis-retinol through a proposed SN1 O-alkyl bond cleavage. RPE65's combination of an O-alkyl ester cleavage, geometric isomerization, and water addition is currently thought to be unique in biology. However, O-alkyl ester cleavage reactions with similarly stabilized carbocation intermediates are used by organic chemists.[9][17]

O-Alkyl cleavage

The O-alkyl cleavage of the ester bond, assisted by an Fe(II) cofactor, creates a carbocation intermediate that is stabilized by the conjugated polyene chain. The delocalization of the carbocation reduces the bond order of the polyene chain, thereby reducing the activation energy of the trans-to-cis isomerization. Phe103 and Thr178 additionally stabilize the isomerized carbocation and are thought to be responsible for the stereoselectivity of the enzyme. After isomerization, a nucleophilic attack by water at C15 restores the conjugation of the polyene chain and completes the ester bond cleavage.[9][13]

Alternate SN2 mechanism

Nearly all other biochemical ester hydrolysis reactions occur through SN2 reaction at the acyl carbon. However, isotope labeling studies have demonstrated that the oxygen on the final 11-cis-retinol product of RPE65 originates from the solvent rather than the reacting ester, supporting the O-alkyl cleavage mechanism.[13] Additionally, an SN2 ester hydrolysis reaction mechanism would rely on a separate, unfavorable SN2 attack at electron rich C11 by some nucleophile - most likely a cystine residue - to complete the isomerization portion of the reaction. Not only is nucleophilic attack of an alkene energetically unfavorable, but the active site region is lacking cystine residues to act as the nucleophile.[8][9]

Clinical significance

Mutations in this gene have been associated with Leber's congenital amaurosis type 2 (LCA2) and retinitis pigmentosa (RP).[6][18] RPE65 mutations are the most commonly detected mutations in LCA patients in Denmark.[19] The vast majority of RPE65 mutations in patients with LCA2 and RP occur in the beta-propeller regime and are believed to inhibit proper protein folding and iron cofactor binding. Particularly common propeller mutation sites are Tyr368 and His182. Substitution at Arg91 is also common and have been shown to impact RPE65 membrane interactions and substrate uptake.[13]

Though complete loss of function is associated with diseases such as LCA and RP, partial inhibition of RPE65 has been proposed as a treatment for age-related macular degeneration (AMD). All-trans-retinylamine (Ret-NH2) and emixustat have both been shown to competitively inhibit RPE65.[9] Emixustat is currently undergoing FDA phase 3 clinical trials as a therapy for AMD.[9][20]

Jean Bennett and Katherine A. High's work with the RPE65 mutation has reversed an inherited form of blindness. They received the first FDA approval of a gene therapy for a genetic disease, which is called Voretigene neparvovec. For their scientific achievements Jean Bennett and Katherine A. High were named as one of three finalists in 2018 for Sanford Health's $1 million Lorraine Cross Award for innovation in science and medicine.

See also

References

  1. ^ a b c GRCh38: Ensembl release 89: ENSG00000116745Ensembl, May 2017
  2. ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000028174Ensembl, May 2017
  3. ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  5. ^ Hamel CP, Tsilou E, Pfeffer BA, Hooks JJ, Detrick B, Redmond TM (Jul 1993). "Molecular cloning and expression of RPE65, a novel retinal pigment epithelium-specific microsomal protein that is post-transcriptionally regulated in vitro". The Journal of Biological Chemistry. 268 (21): 15751–7. doi:10.1016/S0021-9258(18)82319-5. PMID 8340400.
  6. ^ a b "Entrez Gene: RPE65 retinal pigment epithelium-specific protein 65kDa".
  7. ^ Wolf G (Mar 2005). "Function of the protein RPE65 in the visual cycle". Nutrition Reviews. 63 (3): 97–100. doi:10.1111/j.1753-4887.2005.tb00127.x. PMID 15825812.
  8. ^ a b c d e f g h i Kiser PD, Palczewski K (Sep 2010). "Membrane-binding and enzymatic properties of RPE65". Progress in Retinal and Eye Research. 29 (5): 428–42. doi:10.1016/j.preteyeres.2010.03.002. PMC 2903629. PMID 20304090.
  9. ^ a b c d e f g h i j k l Kiser PD, Zhang J, Badiee M, Li Q, Shi W, Sui X, Golczak M, Tochtrop GP, Palczewski K (Jun 2015). "Catalytic mechanism of a retinoid isomerase essential for vertebrate vision". Nature Chemical Biology. 11 (6): 409–15. doi:10.1038/nchembio.1799. PMC 4433804. PMID 25894083.
  10. ^ Tang, Peter H.; Buhusi, Mona C.; Ma, Jian-Xing; Crouch, Rosalie K. (2011-12-14). "RPE65 is present in human green/red cones and promotes photopigment regeneration in an in vitro cone cell model". The Journal of Neuroscience. 31 (50): 18618–18626. doi:10.1523/JNEUROSCI.4265-11.2011. ISSN 1529-2401. PMC 3297673. PMID 22171060.
  11. ^ Kiser PD, Golczak M, Palczewski K (Jan 2014). "Chemistry of the retinoid (visual) cycle". Chemical Reviews. 114 (1): 194–232. doi:10.1021/cr400107q. PMC 3858459. PMID 23905688.
  12. ^ Orban T, Jastrzebska B, Palczewski K (Apr 2014). "Structural approaches to understanding retinal proteins needed for vision". Current Opinion in Cell Biology. 27: 32–43. doi:10.1016/j.ceb.2013.11.001. PMC 3971393. PMID 24680428.
  13. ^ a b c d e f g h Kiser PD, Golczak M, Lodowski DT, Chance MR, Palczewski K (Oct 2009). "Crystal structure of native RPE65, the retinoid isomerase of the visual cycle". Proceedings of the National Academy of Sciences of the United States of America. 106 (41): 17325–30. doi:10.1073/pnas.0906600106. PMC 2765077. PMID 19805034.
  14. ^ Takahashi, Yusuke; Moiseyev, Gennadiy; Ma, Jian-xing (2014-09-26). "Identification of key residues determining isomerohydrolase activity of human RPE65". The Journal of Biological Chemistry. 289 (39): 26743–26751. doi:10.1074/jbc.M114.558619. ISSN 1083-351X. PMC 4175317. PMID 25112876.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ Jin M, Li S, Moghrabi WN, Sun H, Travis GH (Aug 2005). "Rpe65 is the retinoid isomerase in bovine retinal pigment epithelium". Cell. 122 (3): 449–59. doi:10.1016/j.cell.2005.06.042. PMC 2748856. PMID 16096063.
  16. ^ Ma J, Zhang J, Othersen KL, Moiseyev G, Ablonczy Z, Redmond TM, Chen Y, Crouch RK (Jun 2001). "Expression, purification, and MALDI analysis of RPE65". Investigative Ophthalmology & Visual Science. 42 (7): 1429–35. PMID 11381042.
  17. ^ Redmond, T. Michael; Poliakov, Eugenia; Kuo, Stephanie; Chander, Preethi; Gentleman, Susan (2010-01-15). "RPE65, visual cycle retinol isomerase, is not inherently 11-cis-specific: support for a carbocation mechanism of retinol isomerization". The Journal of Biological Chemistry. 285 (3): 1919–1927. doi:10.1074/jbc.M109.027458. ISSN 1083-351X. PMC 2804350. PMID 19920137.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  18. ^ Bowne SJ, Humphries MM, Sullivan LS, Kenna PF, Tam LC, Kiang AS, Campbell M, Weinstock GM, Koboldt DC, Ding L, Fulton RS, Sodergren EJ, Allman D, Millington-Ward S, Palfi A, McKee A, Blanton SH, Slifer S, Konidari I, Farrar GJ, Daiger SP, Humphries P (Oct 2011). "A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement". European Journal of Human Genetics. 19 (10): 1074–81. doi:10.1038/ejhg.2011.86. PMC 3190249. PMID 21654732.
  19. ^ Astuti GD, Bertelsen M, Preising MN, Ajmal M, Lorenz B, Faradz SM, Qamar R, Collin RW, Rosenberg T, Cremers FP (Dec 2015). "Comprehensive genotyping reveals RPE65 as the most frequently mutated gene in Leber congenital amaurosis in Denmark". European Journal of Human Genetics. 24 (7): 1071–1079. doi:10.1038/ejhg.2015.241. PMC 5070892. PMID 26626312.
  20. ^ "Acucela - Retinal Diseases". acucela.com. Retrieved 2016-03-01.

Further reading

Protein Structure and Function
Clinical and Genetic Studies